After scuppered Sanofi deal, Maze navigates its way to new partner for Pompe drug

2024-05-10

交易

临床1期

Maze Therapeutics looks to have found another partner for its investigational Pompe disease drug MZE001 after a deal last year with Sanofi fell foul of antitrust regulators. In an agreement announced on Friday, Maze will receive $150 million upfront from Shionogi and is eligible for additional milestones payments and tiered sales royalties.

Sanofi abandoned its plans to license the Maze molecule in December under a deal potentially worth $750 million, including $150 million upfront, after the US Federal Trade Commission (FTC) raised competition concerns. The French drugmaker already markets the Pompe disease enzyme replacement therapies Lumizyme (alglucosidase alfa), also known as Myozyme, and Nexviazyme (avalglucosidase alfa), which are both administered via biweekly intravenous infusions.

Meanwhile, Shionogi is looking to strengthen its rare diseases portfolio as part of its revised medium-term business strategy. “The science behind MZE001 is differentiated and promising,” with the potential to serve as “both mono and add-on therapy to enzyme replacement therapies,” remarked Shionogi CEO Isao Teshirogi.

MZE001, an oral inhibitor of GYS1, is designed to restrict glycogen accumulation in patients with Pompe disease. The drug’s Phase I data released in February last year confirmed target engagement, prompting Maze to finalise mid-stage development. As part of the deal for MZE001, Shionogi will also have global rights to related programmes and intellectual property.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构